Cargando…
A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation
Gaucher disease is a progressive lysosomal storage disorder caused by the deficiency of glucocerebrosidase leading to the dysfunction in multiple organ systems. Intravenous enzyme replacement is the accepted standard of treatment. In the current report, we evaluate the safety and pharmacokinetics of...
Autores principales: | Aviezer, David, Brill-Almon, Einat, Shaaltiel, Yoseph, Hashmueli, Sharon, Bartfeld, Daniel, Mizrachi, Sarah, Liberman, Yael, Freeman, Arnold, Zimran, Ari, Galun, Eithan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652073/ https://www.ncbi.nlm.nih.gov/pubmed/19277123 http://dx.doi.org/10.1371/journal.pone.0004792 |
Ejemplares similares
-
Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems
por: Tekoah, Yoram, et al.
Publicado: (2013) -
Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis
por: Ilan, Yaron, et al.
Publicado: (2016) -
Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016) -
Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis: Results From a Phase 2a Clinical Trial
por: Almon, Einat, et al.
Publicado: (2021) -
DNA damage alters EGFR signaling and reprograms cellular response via Mre-11
por: Volman, Yael, et al.
Publicado: (2022)